drugset / Trial / NCT02276352

Relative Bioavailability of Meloxicam 2 x 7.5 mg Tablets Compared to 15 mg Tablet and Dose Proportionality Over a Dose Range of 7.5 mg and 15 mg in Healthy Volunteers

NCT02276352

Phase 1 Completed 18 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Study to assess the relative bioavailability of two 7.5 mg meloxicam tablets (American type) compared to one 15 mg meloxicam tablet (American type), and to investigate dose-proportionality over the dosage range 7.5 mg to 15 mg

Timeline

Start
1999-06
Primary completion
1999-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Meloxicam Small molecule 7.5 mg Oral
Subject Meloxicam Small molecule 15 mg Oral

Indications

No indication recorded.